AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD
NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").
- NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").
- The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.
- Each year, over 8.6 million adults grapple with PTSD, and nearly ten percent of Americans will experience PTSD at some time in their lives.
- Currently, no academic institution, other than the Center, is conducting research involving the administration of psychedelics inside the VA System.